◆ 会议时间：2026年10月21-23日
◆ 会议地点：加拿大 多伦多
◆ 会议简介：
2026年第10届美国多发性硬化症治疗和研究委员会(ACTRIMS)与欧洲多发性硬化症治疗与研究委员会(ECTRIMS)联合会议将于2026年10月21-23日在加拿大多伦多举行。届时将汇聚来自世界各地的研究人员、临床医生、医疗保健从业人员和行业合作伙伴，共同分享知识、建立联系，并探讨多发性硬化症和其他脱髓鞘疾病的最新进展。ACTRIMS和ECTRIMS每三年联合举办一次会议。
10th Joint ECTRIMS-ACTRIMS Meeting
Date:
October 21 - 23, 2026
Venue：
Toronto, Canada
Organized by:
Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)
European Committee for Treatment and Research in Multiple Sclerosis(ECTRIMS)
摘要征文投稿：
-
March 24, 2026
Regular Abstract Submission Opens
-
May 7, 2026
Regular Abstract Submission Closes
-
May 12, 2026
Late-Breaking Abstract Submission Opens
-
July 16, 2026
Late-Breaking Abstract Submission Closes
-
Late July 2026
Notification of Abstracts
-
Late August 2026
Notification of Late-Breaking Abstracts
点此提交摘要>>>Submit Abstract>>>
点此查看更多摘要相关信息>>>
Prepare your submission using this manual—download it and work through each section to ensure all required information is ready for your abstract.
Abstract Preparation
- Abstracts must be submitted online via the abstract submission site. Abstracts submitted by email or fax will not be accepted.
- Abstracts must be submitted in English. Please use American English spelling.
- Titles must be submitted in title case (e.g., “Safety of New MS Therapies”) and may not exceed 250 characters, including spaces.
- The abstract must include five required sections: Background, Objectives, Methods, Results, and Conclusions. The full abstract text may not exceed 2,550 characters (approx. 300 words), including headings and spaces, excluding disclosures.
- Case reports are generally discouraged. Exceptions may be considered if they provide significant insights or contribute uniquely to the field.
- All abbreviations (except MS) must be defined the first time they appear in the text (e.g., Multiple Sclerosis Impact Scale [MSIS]). Do not define abbreviations in the title.
- Use the abstract submission site functions for Greek letters, mathematical symbols, special characters, and formatting. Avoid complex mathematical formulae.
- Use generic drug names.
- Do not include tables, charts, or figures— these will be deleted.
- Source(s) of research funding or study support must be identified in the abstract at the time of submission in the Funding Source section of the abstract submission.
- A primary keyword must be selected during abstract submission (see list below).
- Authors must indicate their presentation preference during abstract submission: oral or poster presentation OR poster presentation only.
- The presenting author of an accepted abstract must register and attend MSToronto2026.
- You may edit your abstract until the submission deadline. After the deadline, no changes will be accepted. If you re-open a submitted abstract, you must re-submit the abstract again.
- Ensure your email address is correct. After submission, the submitter will receive a confirmation email with a PDF of the abstract and an abstract number for reference. If you do not receive a confirmation email, please contact abstracts.mstoronto@congrex.com.
- Duplicate submissions are not permitted. Authors may not submit multiple abstracts derived from the same study or dataset with only minor changes to the title, scope, or level of data completeness. The Scientific Program Committee reserves the right to reject duplicate submissions at any stage of the review process, or after presentation, if duplication is identified.
Dear Colleagues,
We are pleased to invite you to MSToronto2026, the 10th Joint ACTRIMS-ECTRIMS Meeting, taking place October 21–23, 2026, at the Metro Toronto Convention Centre in Toronto, Canada.
Every three years, ACTRIMS and ECTRIMS come together to host a joint meeting. MSToronto2026 will mark the 10th such gathering, uniting researchers, clinicians, healthcare practitioners, and industry partners from around the world to share knowledge, build connections, and explore the latest advancements in multiple sclerosis and other demyelinating diseases.
Guided by the theme “Unifying Multiple Sclerosis,” this meeting reflects scientific progress in the field, recognizing that MS is one disease—affecting people of all races and geographies—diagnosed within a unified framework and described through a unified clinical course.
The scientific program will include:
- Plenary lectures from leading experts
- Scientific and educational sessions on cutting-edge MS research, diagnostics, and treatment approaches
- Platform presentations highlighting novel discoveries and clinical applications
- Poster sessions showcasing groundbreaking work
- Satellite symposia featuring industry innovation
- And numerous networking opportunities to build collaboration and community
We look forward to continuing important initiatives at MSToronto2026, including a Pre-Day focused on rare diseases connected with MS and a Patient Community Day designed to foster meaningful dialogue between the scientific community and those living with MS.
Set against the backdrop of Toronto, a city celebrated for its multicultural diversity, vibrant arts scene, and world-class attractions, MSToronto2026 promises to be an exceptional gathering that advances both knowledge and clinical practice.
We acknowledge that the land on which we will meet is the traditional territory of many nations, including the Mississaugas of the Credit, the Anishnabeg, the Chippewa, the Haudenosaunee, and the Wendat peoples, and is now home to many diverse First Nations, Inuit, and Métis peoples.
On behalf of the ACTRIMS and ECTRIMS Board of Directors and the Scientific Program Committee, we appreciate your participation and look forward to an inspiring and impactful meeting.
Sincerely,
Daniel Ontaneda
Scientific Program Committee Chair
ACTRIMS Director
Olga Ciccarelli
Scientific Program Committee Vice Chair
ECTRIMS Vice President
◆ 参会对象：医生、医院科室主任/副主任、住院医师、医院管理者、医护人员以及从事该领域研究的科学家、研究人员、医药企业代表等等。
|
